Serologic Procedures and Test Results

Serologic procedures convert an antigen-antibody reaction into a visible, enzymatic, fluorescent, or electronic signal, and each format determines what a result can mean, which control proves the run was valid, and which interference can distort it. This page covers the reaction formats and the interpretation rules specific to them. General quality assessment and the sensitivity, specificity, and predictive-value mathematics that sit under every interpretation belong to Laboratory Operations, and measurement of analyte-specific immunoassays belongs to Chemistry.

Precipitation and agglutination

The lattice principles behind precipitin lines, reaction zones, and titer interpretation are covered in Antigen-Antibody Interactions and Complement. This section covers the procedure formats built on those principles.

Precipitation forms a visible lattice from soluble antigen and antibody. Ouchterlony double immunodiffusion places antigen and antisera in wells cut into an agarose gel and lets each diffuse toward the other; precipitin lines form where concentrations reach equivalence, and comparing control and unknown wells gives three patterns: fused, continuous lines show identity, crossing lines show nonidentity, and a fused line with a spur shows partial identity, where one antigen shares an epitope with a second and carries an additional one. The method classically separates anti-Sm from anti-RNP sera because RNP travels bound to Sm inside the nucleus. Immunodiffusion remains a reference method for resolving which extractable nuclear antigen an antibody recognizes, with high specificity and low throughput.¹

Flocculation is precipitation confined to a narrow antigen-concentration window; the VDRL and RPR flocculation assays apply it to lipoidal antigens as described in Syphilis, Lyme, and Tuberculosis Serology.¹

Agglutination applies the same cross-linking to particulate antigen: whole cells, or inert particles coated in advance with antigen or antibody.

The inhibition formats read in the opposite direction from the others: no clumping is the positive outcome. Cryptococcal antigen testing by latex agglutination works in the reverse-passive direction; lateral-flow cryptococcal antigen assays are generally preferred where available because they are rapid and simple.¹

Agglutination and precipitation assays are fast, portable, inexpensive, and instrument-free, which suits them to pathogens that are dangerous or slow to culture. Their controls and conditions matter together: antigen concentration, incubation time and temperature, diluent, and reading method all shift the equivalence point and must run exactly as validated, with each new reagent lot verified because kit sensitivity and specificity differ across manufacturers. An unexpected positive is investigated for cross-reactivity first, in which an antibody binds a structurally similar epitope; monoclonal reagents aimed at a single epitope minimize that risk. A negative result always leaves the analyte’s detection threshold in play, so a negative early-window serologic test is repeated on the schedule its algorithm defines.¹

Labeled immunoassays

Two design questions divide the labeled formats: how bound and free label are separated, and whether patient analyte competes with the reagent or is captured between two antibodies.¹

Separation. Heterogeneous assays physically separate bound from free label with a wash, magnetic capture, or centrifugation before reading. Homogeneous assays are engineered so that bound and free label signal differently in the same tube, trading some analytical sensitivity for speed and full automation.¹

Binding format. Competitive assays give labeled and patient analyte a fixed, limited number of antibody sites, so more patient analyte leaves less bound label: the signal runs inverse to concentration, and the design suits small haptens that cannot bind two antibodies at once. Sandwich (capture) assays use excess capture antibody, so essentially all patient analyte binds, and a labeled second antibody against a different epitope completes the sandwich; the signal rises directly with analyte and requires a large enough analyte to present two distinct epitopes.¹

Competitive behavior follows the law of mass action. With 90 units of labeled antigen competing for 55 antibody binding sites, the labeled share of the bound fraction behaves as the patient analyte rises:

Calibrators at known concentrations generate a nonlinear standard curve, linearized mathematically, from which unknown concentrations are read.¹

Historical and current formats

¹,²

Biotin-streptavidin amplification, with biotin on the detection antibody and enzyme-conjugated streptavidin recruiting multiple biotin sites, increases sandwich-assay sensitivity.¹

Interferences

¹,²

FDA’s safety communication warns that high-dose biotin from supplements marketed for hair, skin, and nails has caused falsely low troponin results and other serious misinterpretations in streptavidin-biotin assays, and the agency asks patients to disclose biotin use before testing.² Immunoassays are not standardized across manufacturers because kits target different epitopes, so reference intervals and absolute values differ by platform, and serial results for one patient stay on one method.¹

Immunofluorescence and multiplex bead assays

Direct immunofluorescence carries the fluorochrome on the antibody that recognizes the target. Antigen fixed to a slide, or present on cells, is incubated with the labeled antibody, washed, and read under UV illumination; bright fluorescence on a dark field is positive. The format identifies microbial antigen directly in specimens, with Legionella pneumophila and Chlamydia trachomatis as classical applications, and, read by flow cytometry, it is the basis of leukemia and lymphoma immunophenotyping with CD-marker panels.¹

Indirect immunofluorescence (IIF) adds an amplifying second layer: fixed antigen or cells capture patient antibody, then a fluorescent anti-human-immunoglobulin conjugate binds it. Several labeled secondary molecules can bind each captured primary antibody, so IIF amplifies signal beyond direct labeling, and one anti-human conjugate serves every antigen substrate in the laboratory. IIF detects antigen, with an unlabeled primary first, or antibody, and remains the reference method for HEp-2 ANA screening, Crithidia luciliae anti-dsDNA confirmation, the historical FTA-ABS, VZV FAMA testing, and EBV-specific serology. It is slow, requires a trained reader, and varies with buffer, conjugate, and microscope conditions among laboratories.¹

Multiplex bead immunoassays dye polystyrene beads with unique infrared or fluorescent combinations, giving 100 to 400 distinct identities in commercial platforms, one antigen or one antibody per bead. Flow cytometry reads each bead’s color identity and bound-antibody fluorescence simultaneously, so single-antigen HLA antibody testing, autoantibody panels, donor-specific antibody screening, and cytokine profiling run from one small sample volume.¹

Autoantibody serology

Antinuclear antibodies

Antinuclear antibodies target nuclear components, including dsDNA, histones, nucleosomes, centromere proteins, and the extractable nuclear antigens (Sm, RNP, SS-A/Ro, SS-B/La, Scl-70, Jo-1). ANA appears in more than 95 percent of active lupus and in most other systemic autoimmune rheumatic diseases, some chronic infections, some cancers, pregnancy, up to 5 percent of healthy adults, and about 30 percent of healthy elderly people, so a positive ANA is a sensitive screen with limited specificity.¹

¹

IIF on HEp-2 cells remains the reference ANA screening method: patient serum is incubated on fixed HEp-2 cells, chosen for large nuclei with high antigen density, developed with fluorescein-labeled anti-human immunoglobulin, and read at 400x, usually at screening dilutions of 1:80 to 1:160. The report states the endpoint titer and pattern, and the International Consensus on ANA Patterns (ICAP) standardizes the nomenclature; the current ICAP reference recognizes 31 anti-cellular patterns across nuclear, cytoplasmic, and mitotic categories, coded AC-1 through AC-31 plus AC-XX for unassigned patterns.¹,³ A negative ANA result does not exclude SLE, since about 5 percent of patients test negative.¹

Solid-phase assays (ELISA, chemiluminescent, multiplex bead) anchor a defined nuclear antigen panel to a plate, membrane, or bead and read bound antibody with labeled anti-human immunoglobulin. They are faster and more objective than IIF but less sensitive as a screen, so professional guidance retains IIF as the reference screening method.¹ Crithidia luciliae immunofluorescence confirms anti-dsDNA specifically: the kinetoplast of this trypanosome is an organelle of nearly pure dsDNA, so bright kinetoplast staining gives a specific signal free of the ssDNA reactivity that contaminates other substrates.¹

Thyroid autoantibodies

Thyroid testing begins with TSH, sensitive down to 0.01 mU/L; because pituitary feedback follows free hormone, an abnormal TSH prompts free T4 measurement, preferred over total T3 and T4, which fluctuate with binding proteins. Anti-thyroid peroxidase (anti-TPO) is the more sensitive marker of Hashimoto’s thyroiditis, positive in up to 95 percent of patients against 10 to 15 percent of the general population, while anti-thyroglobulin is less sensitive and negative results occur in disease. In Graves’ disease, TSH-receptor antibodies (TRAbs) are the diagnostic marker, positive in 98 to 100 percent of patients.¹

TRAb testing separates two formats. Binding assays are automated ELISAs or chemiluminescent immunoassays in competitive format against solid-phase TSH receptor; they measure total TRAb and cannot distinguish stimulating from blocking antibody. Bioassays use living TSH-receptor-bearing cells and read cyclic-AMP-driven luciferase activation; they are technically demanding reference-laboratory tests that detect stimulating activity and can track TSI titer during therapy and predict neonatal thyroid dysfunction risk in a mother with Graves’ disease.¹

Rheumatoid factor and anti-CCP

Rheumatoid factor (RF), usually IgM against the Fc region of IgG, appears in 70 to 90 percent of rheumatoid arthritis patients and also in about 5 percent of healthy adults, 10 to 25 percent of people over 65, other rheumatic diseases, and chronic infection, so a negative RF result does not exclude RA and a positive one does not confirm it. Routine agglutination, turbidimetric, and nephelometric methods predominantly detect IgM RF; isotype-specific immunoassays extend measurement to IgG and IgA RF.¹

Anti-cyclic citrullinated peptide (anti-CCP) antibody joins the 2010 ACR/EULAR RA classification criteria for its specificity, about 95 percent alone. It appears in many RF-negative patients, can precede clinical onset by years, predicts more aggressive disease, and combined RF plus anti-CCP testing raises specificity to 98 to 100 percent. Disease activity is tracked with ESR and CRP, which rise with inflammation, and with complement: in RA, complement is typically normal or elevated with the acute-phase response, in contrast with the consumption of active SLE.¹

Cytokine assays

Three assay families serve clinical cytokine profiling for autoimmune disease, infection, allergy, and inflammatory states. Multiplexed ELISAs and microarrays measure several cytokines from one sample, each in its own well or array spot with paired controls. Microbead assays measure up to about 100 analytes per tube with colored, antigen- or antibody-coated beads read by flow cytometry, using the multiplex principle described above; measured analytes include acute-phase reactants such as CRP, Th1 and Th2 discriminators such as IFN-gamma, IL-2, IL-4, IL-5, and IL-10, and colony-stimulating factors.¹

ELISpot counts individual cytokine-secreting cells; the other two families measure total cytokine mass. Peripheral blood mononuclear cells isolated by gradient centrifugation are plated on capture-antibody-coated wells and stimulated with antigen; a sandwich-format detection step then leaves a countable spot of captured cytokine directly beneath each responding cell. T-SPOT.TB applies this principle to M. tuberculosis exposure, as described in Syphilis, Lyme, and Tuberculosis Serology.¹

Test result interpretation

Reading agglutination and labeled-assay results

The reaction conditions and lot-verification rules from the agglutination section govern day-to-day interpretation: an unexpected positive is investigated for cross-reactivity first, and reagents run within their validated life with verified lots. Inhibition formats invert the reading direction, so the absence of agglutination is the reactive outcome, and misreading that direction is the classic error this group of assays produces.¹

Confirmatory testing after screening

Immunoassay screens are presumptive, so a positive screen triggers a chemically or immunologically different confirmatory method in every mature algorithm: HIV screening reflexes to antibody differentiation, syphilis reflexes across the nontreponemal (lipoidal antigen) and treponemal divide, Lyme reflexes from a first-tier immunoassay to immunoblot or a paired EIA, and anti-dsDNA screening by solid-phase assay confirms on Crithidia luciliae substrate.¹

Complement interpretation

CH50 and AH50 pathway screens, their preanalytic requirements, and the follow-up of abnormal screens with component-specific antigenic and functional testing are covered in Antigen-Antibody Interactions and Complement. Loss of one C1 subcomponent can leave the other two antigenically present while function is lost, and C2 antigen can persist despite absent function, so antigenic measurement alone cannot exclude a functional defect.¹

Immunodeficiency confirmatory testing

When screening or clinical findings suggest immunodeficiency, confirmatory tests narrow the defect to a compartment: humoral defects prompt B-cell counts by flow cytometry and in vitro B-cell proliferation testing; cell-mediated defects prompt T-cell subset counts, lymphocyte proliferation to mitogens and recall antigens, and adenosine deaminase and purine-nucleoside phosphorylase enzyme assays; phagocyte defects prompt adhesion-molecule analysis (CD11a/b/c, CD18), phagocytosis and killing assays, chemotaxis, and myeloperoxidase, G6PD, and NADPH-oxidase component assays; complement defects are resolved with the component assays described on the complement page.¹

Flow cytometry is central to that workup: fluorescent antibodies against CD markers on peripheral blood mononuclear cells after red-cell lysis identify the reduced CD3 population of partial DiGeorge syndrome, the absent CD3 population of complete DiGeorge syndrome, and the absent CD19 population of Btk deficiency. Secondary immunodeficiency complicates the read: an absent B-cell result occurs after rituximab, an anti-CD20 monoclonal that depletes CD19-positive and CD20-positive B cells, so medication history is reviewed before genetic testing is pursued. IGRA platforms measure M. tuberculosis-specific responses and are not general cellular-immunity tests, and commercial ATP-release assays used in some transplant settings are not validated substitutes for standard inborn-error-of-immunity functional testing. Molecular testing is recommended for suspected SCID and many inborn errors of immunity, with clinical management never delayed for its results.¹,³

General principles of serologic diagnosis

Serology remains the practical diagnostic route for organisms that culture poorly or slowly, including Anaplasma, Ehrlichia, Chlamydia species, Coxiella burnetii, Leptospira, Rickettsia species, and T. pallidum. Interpretation follows the timing rules the organism pages describe: IgM commonly takes 7 to 10 days to become detectable after infection, so a rapidly progressing infection can require treatment before serologic confirmation is possible, and a high single IgG titer can reflect an old infection with no relation to the current illness. Paired acute and convalescent samples, run side by side in the same assay run, resolve that ambiguity whenever the clinical timeline allows a second specimen.¹